| Revenue growth | 22% YoY growth to ₹14,768 Mn. |
|---|---|
| Margins | Gross margin expanded 74 bps YoY to 65.6% on portfolio enrichment. |
| Demand visibility | Strong, powered by 25 ANDAs under approval with $40Bn US TAM. |
| Management confidence | High, citing stronger organization and clear strategic priorities for sustainable growth. |
Growth
Revenue reached ₹14,768 Mn (+22% YoY). EBITDA grew 37% YoY to ₹3,389 Mn with margins expanding 256 bps to 22.9%.
Outlook
Focus on Complex Gx (now 50% of FD portfolio), Peptide CDMO ramp-up, and R&D investment (6% of sales).
Risks
External cost pressures and supply chain volatility require continuous management for the next few quarters.
Last quarter's promises, checked
Delivered
- Targeted PAT positive peptides for FY27 → delivered quarterly run rate of INR60Cr (= BEAT)
- Guided 33% working capital to sales → delivered 29% (= BEAT)
- Guided INR600Cr total annual capex → delivered INR89Cr in Q1 (= BEAT)
Partly delivered
- Guided Q4 breakeven for peptide EBITDA → delivered INR12Cr loss in Q1 (= PARTIAL)
Earnings Call Transcript filed with NSE, NSE: GRANULES. Summary written with AI assistance from the document.
Granules India Ltd: key numbers
- Share price
- ₹868.65
- Market cap
- ₹21,525 Cr
- Revenue (annual)
- ₹5,366 Cr
- Net profit (annual)
- ₹595.0 Cr
- P/E (TTM)
- 32.5×Sector 50.4×
- Promoter holding
- 37.39%-0.63% QoQ
- FII holding
- 20.29%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Granules India Ltd
All →Granules India Promoter Buying
Promoter Uma Devi Chigurupati acquired 2.48 crore shares of Granules India Ltd via the open market. This transaction increases the promoter stake by 8.70%.
- Promoter stake change
- +8.70%
Granules India Other Announcement
The company submitted its quarterly shareholding pattern disclosure as required by SEBI regulations for the period ended September 16, 2026.
Granules India Capital Structure Change
Granules India allotted 2.49 crore equity shares to its promoter group upon warrant conversion, raising Rs. 1,461.50 Crore. This increases the company's total paid-up equity capital.
- Value
- ₹1,462 Cr
Granules India Capital Structure Change
Granules India received Rs. 1,093 crore from the Promoter group, representing the balance 75% subscription for the conversion of 2.49 crore warrants into equity shares.
- Value
- ₹1,093 Cr
Granules India Promoter Selling
Promoter Dr. Krishna Prasad Chigurupati sold 1.72 crore equity shares of Granules India Ltd via block deal and open market, reducing aggregate promoter stake.
- Promoter stake change
- -6.94%
Granules India Earnings Call Transcript: Key Takeaways
Granules India delivered record Q1 results, pivoting from volume-driven to a higher-margin complex generic and peptide-led platform. Profitability grew 60% YoY despite regulatory headwinds at Gagillapur, highlighting strong execution and diversification into regulated markets.
- Call
- Guides 400% growth